AbCellera Biologics (NASDAQ:ABCL) Issues Quarterly Earnings Results, Beats Expectations By $0.08 EPS

AbCellera Biologics (NASDAQ:ABCL) released its quarterly earnings results on Monday. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.08, FiscalAI reports. The business had revenue of $8.32 million for the quarter, compared to analysts’ expectations of $5.86 million. AbCellera Biologics had a negative net margin of 198.37% and a negative return on equity of 15.05%.

Here are the key takeaways from AbCellera Biologics’ conference call:

• Interim Phase I data for ABCL635 showed generally well‑tolerated safety with no liver‑related adverse events, linear PK supporting monthly dosing, and sustained dose‑dependent suppression of testosterone, FSH and LH consistent with strong NK3R target engagement.
• The randomized Phase II (≈80 patients, single 600 mg SC dose) is enrolling and remains on track for a top‑line efficacy/safety readout in Q3 2026; management says a positive result would be highly de‑risking and support late‑stage development and expansion into cancer‑related VMS indications.
• Pipeline progress includes an expected Phase I top‑line for ABCL575 in Q4 2026, two IND‑enabling programs (ABCL688, ABCL386) targeted to reach the clinic by end‑2027, and a planned fifth development candidate selection in H1 2026, though program details remain limited.
• AbCellera ended Q1 with ~CAD 531M cash and marketable securities plus ~CAD 125M committed government funding (≈CAD 655M available liquidity), which management says funds at least three years of pipeline investment despite a Q1 net loss of ~CAD 43M and lower research‑fee revenue as the company shifts to internal programs.

AbCellera Biologics Trading Up 0.2%

NASDAQ:ABCL traded up $0.01 during mid-day trading on Monday, reaching $5.25. The company’s stock had a trading volume of 12,825,868 shares, compared to its average volume of 4,789,828. AbCellera Biologics has a 12-month low of $1.94 and a 12-month high of $6.51. The firm’s fifty day moving average price is $3.70 and its two-hundred day moving average price is $3.84. The stock has a market cap of $1.60 billion, a P/E ratio of -10.71 and a beta of 1.02.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ABCL. Weiss Ratings reiterated a “sell (d-)” rating on shares of AbCellera Biologics in a report on Monday, April 20th. Cantor Fitzgerald began coverage on shares of AbCellera Biologics in a report on Tuesday, May 5th. They set an “overweight” rating and a $7.00 target price on the stock. Wall Street Zen upgraded shares of AbCellera Biologics from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Finally, JonesTrading began coverage on shares of AbCellera Biologics in a report on Friday, April 10th. They set a “buy” rating and a $11.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.17.

Hedge Funds Weigh In On AbCellera Biologics

Several institutional investors have recently made changes to their positions in the business. Invesco Ltd. lifted its stake in shares of AbCellera Biologics by 27.9% in the 4th quarter. Invesco Ltd. now owns 54,603 shares of the company’s stock worth $187,000 after purchasing an additional 11,914 shares during the period. XTX Topco Ltd bought a new position in shares of AbCellera Biologics in the 4th quarter worth approximately $1,242,000. nVerses Capital LLC bought a new position in shares of AbCellera Biologics in the 4th quarter worth approximately $121,000. Voloridge Investment Management LLC lifted its stake in shares of AbCellera Biologics by 170.0% in the 4th quarter. Voloridge Investment Management LLC now owns 695,796 shares of the company’s stock worth $2,380,000 after purchasing an additional 438,061 shares during the period. Finally, Virtus Investment Advisers LLC lifted its stake in shares of AbCellera Biologics by 103.4% in the 4th quarter. Virtus Investment Advisers LLC now owns 73,488 shares of the company’s stock worth $251,000 after purchasing an additional 37,365 shares during the period. Institutional investors own 61.42% of the company’s stock.

About AbCellera Biologics

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.